Wednesday, January 22, 2020 Daily Archives

Thermo Fisher envisions 25% annual growth for gene therapy biz and no slowdown

by

Thermo Fisher claims to be the “leading outsource provider of viral vector manufacturing,†nine months after entering the space through the acquisition of Brammer. In March 2019, Thermo Fisher expanded its presence in the CDMO space by announcing plans to buy viral vector manufacturer Brammer Bio. Weeks later, the $1.7 billion deal closed, propelling Thermo Fisher into the gene therapy manufacturing space. Nine months on and Thermo Fisher CEO Marc Casper said the business has “got off to a good…

January 22, 2020

Phacilitate 2020: FDA commercial cell and gene therapy forecast ‘unlikely’

by

Manufacturing issues and a scarcity of new commercial products leave predictions that 10-20 cell and gene therapy approvals each year by 2025 somewhat fanciful, says Dark Horse Consulting. In his plenary address at the Phacilitate conference yesterday, Anthony Davies, founder of cell and gene therapy specialist firm Dark Horse Consulting, reflected on the difficulties the sector has faced since the high of 2017 when three products achieved US Food and Drug Administration (FDA) approval: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel),…

January 22, 2020

GE Healthcare building Swiss cell processing kit plant

by

GE Healthcare Life Sciences says a single-use kit plant it is building in Grens, Switzerland will serve cell and gene therapy firms in the EU and beyond. The 7,360 square meter facility will be located in Grens near the French border. According to GE Life Sciences the facility will meet global regulatory requirements. A spokesperson told us: “The new site will manufacture the single use kits for Sepax and Sefia cell processing systems and will allow us to increase our…

January 22, 2020